Head-To-Head Comparison: Inotiv (NASDAQ:NOTV) & SciSparc (NASDAQ:SPRC)

Inotiv (NASDAQ:NOTV) and SciSparc (NASDAQ:SPRC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, analyst recommendations, profitability and dividends.

Analyst Ratings

This is a summary of current recommendations and price targets for Inotiv and SciSparc, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inotiv	1	0	1	0	2.00
SciSparc	1	0	0	0	1.00

Inotiv currently has a consensus target price of $1.50, suggesting a potential upside of 415.46%. Given Inotiv’s stronger consensus rating and higher probable upside, equities analysts plainly believe Inotiv is more favorable than SciSparc.

Valuation & Earnings

This table compares Inotiv and SciSparc”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inotiv	$513.02 million	0.02	-$68.62 million	($2.03)	-0.14
SciSparc	$856,000.00	3.19	-$12.18 million	N/A	N/A

SciSparc has lower revenue, but higher earnings than Inotiv.

Volatility and Risk

Inotiv has a beta of 3.82, suggesting that its stock price is 282% more volatile than the S&P 500. Comparatively, SciSparc has a beta of 2.71, suggesting that its stock price is 171% more volatile than the S&P 500.

Institutional and Insider Ownership

18.2% of Inotiv shares are owned by institutional investors. Comparatively, 25.1% of SciSparc shares are owned by institutional investors. 7.8% of Inotiv shares are owned by insiders. Comparatively, 1.5% of SciSparc shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Inotiv and SciSparc’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inotiv	-17.14%	-56.77%	-8.91%
SciSparc	N/A	N/A	N/A

About Inotiv

Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company offers research and discovery services, including computational toxicology, disease pharmacology, DMPK, safety pharmacology, discovery bioanalysis, exploratory, surgical models and medical device, and cell and molecular biology; non-clinical safety assessment includes general and genetic toxicology, regulated bioanalysis, carcinogenicity studies, and development and reproductive toxicology; pathology services, such as histology, digital, clinical, and medical device pathology; bioanalysis includes nonregulated discovery bioanalysis, biotherapeutics, and regulated preclinical and clinical bioanalysis; proteomics; and consulting services, as well as model and research services. The company operates in the United States, the Netherlands, and internationally. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.

About SciSparc

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.